Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   37527   clinical trials with a EudraCT protocol, of which   6154   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

    Summary
    EudraCT number
    2017-001042-10
    Trial protocol
    DE   NL  
    Global end of trial date
    08 Nov 2018

    Results information
    Results version number
    v1(current)
    This version publication date
    27 Nov 2019
    First version publication date
    27 Nov 2019
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    VX16-150-102
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03304522
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Vertex Pharmaceuticals Incorporated
    Sponsor organisation address
    50 Northern Avenue, Boston, Massachusetts, United States,
    Public contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617 341 6777, medicalinfo@vrtx.com
    Scientific contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617 341 6777, medicalinfo@vrtx.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    05 Dec 2018
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    12 Oct 2018
    Global end of trial reached?
    Yes
    Global end of trial date
    08 Nov 2018
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the efficacy of VX-150 for the treatment of pain caused by small fiber neuropathy.
    Protection of trial subjects
    The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Council on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    20 Sep 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Italy: 10
    Country: Number of subjects enrolled
    Netherlands: 6
    Country: Number of subjects enrolled
    United States: 71
    Country: Number of subjects enrolled
    Germany: 2
    Worldwide total number of subjects
    89
    EEA total number of subjects
    18
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    66
    From 65 to 84 years
    23
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    A total of 89 subjects were enrolled and randomized in the study.

    Period 1
    Period 1 title
    Overall Trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    VX-150
    Arm description
    Subjects received VX-150 once daily for 6 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    VX-150
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received VX-150 once daily.

    Arm title
    Placebo
    Arm description
    Subjects received placebo matched to VX-150 once daily for 6 weeks.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo (matched to VX-150)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to VX-150 once daily.

    Number of subjects in period 1
    VX-150 Placebo
    Started
    46
    43
    Completed
    45
    35
    Not completed
    1
    8
         Other
    -
    1
         Adverse event
    -
    4
         Withdrawal of consent (for other reason)
    -
    2
         Withdrawal of consent (due to lack of efficacy)
    1
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    VX-150
    Reporting group description
    Subjects received VX-150 once daily for 6 weeks.

    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo matched to VX-150 once daily for 6 weeks.

    Reporting group values
    VX-150 Placebo Total
    Number of subjects
    46 43 89
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    55.1 ± 12.34 58.1 ± 11.86 -
    Gender categorical
    Units: Subjects
        Female
    22 21 43
        Male
    24 22 46

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    VX-150
    Reporting group description
    Subjects received VX-150 once daily for 6 weeks.

    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo matched to VX-150 once daily for 6 weeks.

    Primary: Change From Baseline in Weekly Average of Daily Pain Intensity on the 11 Point Numeric Rating Scale (NRS) Score

    Close Top of page
    End point title
    Change From Baseline in Weekly Average of Daily Pain Intensity on the 11 Point Numeric Rating Scale (NRS) Score
    End point description
    Pain intensity was evaluated using the 11-point NRS (where 0 signified no pain and 10 signified worst imaginable pain).
    End point type
    Primary
    End point timeframe
    At Week 6
    End point values
    VX-150 Placebo
    Number of subjects analysed
    46
    43
    Units: units on a scale
        least squares mean (standard error)
    -2.018 ± 0.274
    -0.933 ± 0.287
    Statistical analysis title
    Statistical Analysis
    Comparison groups
    VX-150 v Placebo
    Number of subjects included in analysis
    89
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    LS Mean Difference
    Point estimate
    -1.085
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.876
         upper limit
    -0.293

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose of study drug up to safety follow-up (up to 10 weeks)
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    21.1
    Reporting groups
    Reporting group title
    VX-150
    Reporting group description
    Subjects received VX-150 once daily for 6 weeks.

    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo matched to VX-150 once daily for 6 weeks.

    Serious adverse events
    VX-150 Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 46 (0.00%)
    3 / 43 (6.98%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    Injury, poisoning and procedural complications
    Tendon rupture
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Diverticulitis
         subjects affected / exposed
    0 / 46 (0.00%)
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    VX-150 Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    16 / 46 (34.78%)
    7 / 43 (16.28%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    11 / 46 (23.91%)
    5 / 43 (11.63%)
         occurrences all number
    14
    6
    Gastrointestinal disorders
    Dry mouth
         subjects affected / exposed
    3 / 46 (6.52%)
    1 / 43 (2.33%)
         occurrences all number
    3
    1
    Nausea
         subjects affected / exposed
    3 / 46 (6.52%)
    1 / 43 (2.33%)
         occurrences all number
    3
    1
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    3 / 46 (6.52%)
    1 / 43 (2.33%)
         occurrences all number
    3
    1
    Muscle spasms
         subjects affected / exposed
    3 / 46 (6.52%)
    0 / 43 (0.00%)
         occurrences all number
    3
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    21 Apr 2017
    Amended inclusion criteria to clarify the study population and Body Mass Index (BMI)
    19 May 2017
    Amended the dose limit of VX-150
    11 Aug 2017
    Allowed inclusion of women of childbearing potential; updated the upper limit of BMI and the visit requirements
    13 Apr 2018
    Updated inclusion and exclusion criteria to facilitate subject recruitment
    25 May 2018
    The protocol was amended to enable timely assessment of study data to support continued development

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA